Prognostic Analysis of Completely Resected Lung Adenocarcinoma with Uncommon EGFR Mutations: CReGYT-01 EGFR Study

被引：0

作者：

Hayasaka, K. ^{[1
,2
]}

Haratake, N. ^{[3
]}

Notsuda, H. ^{[2
]}

Katsumata, S. ^{[1
]}

Hamada, A. ^{[4
]}

Nomura, K. ^{[5
]}

Fujino, K. ^{[6
]}

Yoshikawa, M. ^{[7
]}

Suzawa, K. ^{[7
]}

Shien, K. ^{[7
]}

Suda, K. ^{[4
]}

Ohara, S. ^{[4
]}

Fukuda, S. ^{[4
]}

Kinoshita, I. ^{[3
]}

Takamori, S. ^{[3
,8
]}

Muto, S. ^{[9
]}

Takanashi, Y. ^{[10
]}

Mizuno, K. ^{[10
]}

Kawase, A. ^{[10
]}

Hayakawa, T. ^{[10
]}

Sekihara, K.

Toda, M. ^{[11
]}

Matsuo, S. ^{[12
]}

Takegahara, K. ^{[13
]}

Hashimoto, M. ^{[13
]}

Nakahashi, K. ^{[14
]}

Endo, M. ^{[14
]}

Ozawa, H. ^{[15
]}

Fujikawa, R. ^{[15
]}

Tomioka, Y. ^{[16
]}

Namba, K. ^{[16
]}

Matsubara, T. ^{[17
]}

Suzuki, J. ^{[18
]}

Watanabe, H. ^{[18
]}

Takada, K. ^{[19
]}

Hoshino, H. ^{[20
]}

Toyoda, T. ^{[21
]}

Koki, Y. ^{[22
]}

Shiono, S. ^{[18
]}

Shimokawa, M. ^{[22
]}

Soh, J. ^{[23
]}

Ohde, Y. ^{[1
]}

Okada, Y. ^{[2
]}

机构：

[1] Shizuoka Canc Ctr, Shizuoka, Japan

[2] Tohoku Univ Hosp, Sendai, Miyagi, Japan

[3] Kyushu Univ, Fukuoka, Japan

[4] Kindai Univ, Fac Med, Osaka, Japan

[5] Natl Canc Ctr Hosp East, Kashiwa, Chiba, Japan

[6] Kumamoto Univ, Kumamoto, Japan

[7] Okayama Univ Hosp, Okayama, Japan

[8] Oita Univ, Fac Med, Oita, Japan

[9] Fukushima Med Univ, Sch Med, Fukushima, Japan

[10] Hamamatsu Univ, Sch Med, Shizuoka, Japan

[11] Kansai Rosai Hosp, Amagasaki, Hyogo, Japan

[12] Nihonkai Gen Hosp, Sakata, Yamagata, Japan

[13] Hyogo Coll Med, Nishinomiya, Hyogo, Japan

[14] Yamagata Prefectural Cent Hosp, Yamagata, Japan

[15] Shimada Gen Med Ctr, Shizuoka, Japan

[16] Shimane Univ, Matsue, Shimane, Japan

[17] Kitakyushu Municipal Med Ctr, Fukuoka, Japan

[18] Yamagata Univ, Yamagata, Japan

[19] Saiseikai Fukuoka Gen Hosp, Fukuoka, Japan

[20] NHO Okinawa Hosp, Okinawa, Japan

[21] Chiba Univ, Grad Sch Med, Chiba, Japan

[22] Yamaguchi Univ, Yamaguchi, Japan

[23] Osaka Metropolitan Univ, Grad Sch Med, Osaka, Japan

来源：

JOURNAL OF THORACIC ONCOLOGY | 2024年 / 19卷 / 10期

关键词：

uncommon EGFR mutation; surgery; prognosis;

D O I：

暂无

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

P2.07A.03

引用

页码：S232 / S233

页数：2

共 50 条

[41] Potential Usage of Afanitib in the Treatment of Non-Small-Cell Lung Cancer with Uncommon EGFR Mutations
Harada, Taishi
Yamaba, Yukiko
Hayata, Hiroki
Okuda, Takashi
Kimura, Yoshishige
Komaki, Toshiyuki
Kagawa, Keizo
JOURNAL OF THORACIC ONCOLOGY, 2017, 12 (01) : S1241 - S1241
[42] Prognostic value of EGFR and KRAS in resected non-small cell lung cancer: a systematic review and meta-analysis
Zhang, Shi-Ming
Zhu, Qing-Ge
Ding, Xiao-Xiao
Lin, Song
Zhao, Jing
Guan, Lei
Li, Ting
He, Bing
Zhang, Hu-Qin
CANCER MANAGEMENT AND RESEARCH, 2018, 10 : 3393 - 3404
[43] Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma
Young Joo Lee
In Kyu Park
Moo-Suk Park
Hye Jin Choi
Byoung Chul Cho
Kyung Young Chung
Se Kyu Kim
Joon Chang
Jin Wook Moon
Hoguen Kim
Sung Ho Choi
Joo-Hang Kim
Journal of Cancer Research and Clinical Oncology, 2009, 135 : 1647 - 1654
[44] Activating mutations within the EGFR kinase domain: a molecular predictor of disease-free survival in resected pulmonary adenocarcinoma
Lee, Young Joo
Park, In Kyu
Park, Moo-Suk
Choi, Hye Jin
Cho, Byoung Chul
Chung, Kyung Young
Kim, Se Kyu
Chang, Joon
Moon, Jin Wook
Kim, Hoguen
Choi, Sung Ho
Kim, Joo-Hang
JOURNAL OF CANCER RESEARCH AND CLINICAL ONCOLOGY, 2009, 135 (12) : 1647 - 1654
[45] Outcome of Patients With Resected Early-Stage Non-small Cell Lung Cancer and EGFR Mutations: Results From the IFCT Biomarkers France Study
Mordant, Pierre
Brosseau, Solenn
Milleron, Bernard
Santelmo, Nicola
Fraboulet-Moreau, Severine
Besse, Benjamin
Langlais, Alexandra
Gossot, Dominique
Thomas, Pascal-Alexandre
Pujol, Jean-Louis
Ricordel, Charles
Madelaine, Jeannick
Lamy, Regine
Audigier-Valette, Clarisse
Missy, Pascale
Blons, Helene
Barlesi, Fabrice
Westeel, Virginie
CLINICAL LUNG CANCER, 2023, 24 (01) : 1 - 10
[46] The prognostic implications of EGFR mutation and ALK rearrangement for the long-term outcomes of patients with resected lung adenocarcinomas
Kim, Hyungjin
Lee, Hyun-Ju
Hong, Hyunsook
Kim, Young Jae
Kim, Kwang Gi
Jeon, Yoon Kyung
Kim, Young Tae
THORACIC CANCER, 2019, 10 (07) : 1619 - 1627
[47] Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
Ito, Masaoki
Miyata, Yoshihiro
Kushitani, Kei
Ueda, Daisuke
Takeshima, Yukio
Okada, Morihito
BMC CANCER, 2023, 23 (01)
[48] Distribution and prognostic impact of EGFR and KRAS mutations according to histological subtype and tumor invasion status in pTis-3N0M0 lung adenocarcinoma
Masaoki Ito
Yoshihiro Miyata
Kei Kushitani
Daisuke Ueda
Yukio Takeshima
Morihito Okada
BMC Cancer, 23
[49] Volume-based growth tumor kinetics as a prognostic biomarker for patients with EGFR mutant lung adenocarcinoma undergoing EGFR tyrosine kinase inhibitor therapy: a case control study
Lee, Ji Hyun
Lee, Ho Yun
Ahn, Myung-Ju
Park, Keunchil
Ahn, Jin Seok
Sun, Jong-Mu
Lee, Kyung Soo
CANCER IMAGING, 2016, 16
[50] Clinical Outcomes of Afatinib Versus Osimertinib in Patients With Non-Small Cell Lung Cancer With Uncommon EGFR Mutations: A Pooled Analysis
Wang, Chunsheng
Zhao, Kewei
Hu, Shanliang
Dong, Wei
Gong, Yan
Xie, Conghua
ONCOLOGIST, 2023, 28 (06) : E397 - E405

← 1 2 3 4 5 →